Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • ABTECT
  • Pipeline
    • Overview
    • Patients
    • Obefazimod for UC
    • Obefazimod for Crohn’s
    • Obefazimod for RA
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • General Meeting
  • Contact Us
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

LabioTech

January 18, 2016

A Phase II HIV Antiviral from France Has Promising Results

in-Pharma

July 6, 2015

ABIVAX’s IPO to fund HIV and hep B pipeline before potential Big Pharma deal

in-Pharma

April 14, 2015

Abivax’s ARV action could herald functional HIV cure, says firm

Drug Discovery & Development

December 1, 2014

ABIVAX Completes First-In-Man Study of HIV Treatment

BioSpace

December 1, 2014

ABIVAX successfully completes first-in-man study of ABX464, a highly differentiated small molecule targeting HIV.

  • 1
  • …
  • 44
  • 45
  • 46
© 2023 All rights reserved by ABIVAX | Website created by Stratégie et communication digitale : JLL CONSEIL Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Obefazimod for UC
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • General Meeting
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+